The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982?2001
- 1 March 2005
- journal article
- Published by Springer Nature in International Journal of Health Economics and Management
- Vol. 5 (1) , 47-73
- https://doi.org/10.1007/s10754-005-6601-7
Abstract
We perform an econometric analysis of the effect of new drug launches on longevity, using data from the IMS Health Drug Launches database and the WHO Mortality Database. Under conservative assumptions, our estimates imply that the average annual increase in life expectancy of the entire population resulting from new drug launches is about one week, and that the incremental cost effectiveness ratio (new drug expenditure per person per year divided by the increase in life-years per person per year attributable to new drug launches) is about $6750—far lower than most estimates of the value of a statistical life-year.Keywords
All Related Versions
This publication has 10 references indexed in Scilit:
- The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990sHealth Economics, 2004
- Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of BoneNew England Journal of Medicine, 2003
- Measuring the Gains from Medical ResearchPublished by University of Chicago Press ,2003
- Are The Benefits Of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPSHealth Affairs, 2001
- Is Technological Change In Medicine Worth It?Health Affairs, 2001
- Early Statin Treatment Following Acute Myocardial Infarction and 1-Year SurvivalJAMA, 2001
- Estimated hedonic wage function and value of life in a developing countryEconomics Letters, 1997
- The Economics of New GoodsPublished by University of Chicago Press ,1997
- Do (more and better) drugs keep people out of hospitals?1996
- Endogenous Technological ChangeJournal of Political Economy, 1990